NewsBite analysis · BioTech
MIT News
Tackling rare genetic disorders with patient-focused science
Shannon Knight, currently in her sixth year at MIT’s McGovern Institute for Brain Research, is focused on a novel gene therapy targeting SYNGAP1 haploinsufficiency, a severe genetic disorder causing early-onset epilepsy. This condition, resulting from a mutation in the SYNGAP1 gene, leads to treatment-resistant seizures, impacting a child's development and quality of life. Knight's approach, using CRISPR technology, aims not only to mitigate symptoms but also to address the underlying genetic cause, emphasizing empathy in scientific practice.
MonitorConfidence: HighMid term horizon
Published 18 Aug 2026, 04:15 UTC2 min read
Visit original article ↗Lead image — MIT News
Summary
TL;DR
- Shannon Knight is pursuing a PhD at MIT's McGovern Institute.
- Developing a gene therapy for SYNGAP1 haploinsufficiency.
- The disorder leads to childhood-onset epilepsy and other symptoms.
- Current treatments are often ineffective as children grow.
- CRISPR technology is being utilized in the gene therapy.
- Research emphasizes patient-centered care.
Interesting facts
- SYNGAP1 gene mutations significantly hinder brain development.
- Knight's interest in neuroscience was sparked by a high school experience.